Peripartální kardiomyopatie –
diagnostika a léčba

Česká verzia

Authors: Poloczková H.
Authors place of work: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
Published in the journal: Kardiol Rev Int Med 2018, 20(4): 260-263

Summary

Peripartum cardiomyopathy is a relatively rare disease characterised by systolic heart failure (HF) on the base of left ventricular systolic dysfunction occurring at the end of pregnancy or in the months following the delivery in previously healthy women. The course of the disease may vary, restitution of the left ventricular function is seen in more than 50% of cases, while some patients have a serious course of the disease with progression of HF to cardiogenic shock requiring heart transplantation or mechanical circulatory support. About 20% of patients develop chronic HF with persistent dysfunction of the left ventricle. Early diagnosis and treatment are very important for these patients but may be complicated by the fact that the symptoms are similar to those present in healthy women without heart failure at the end of pregnancy (such as short breath, palpitation, swollen legs or fatigue). The aetiology of the disease is still unclear, the vascular/hormonal hypothesis being most discussed at present. The incidence of the disease varies geographically. The disease appears in 80–90% postpartum, only a small number of cases are diagnosed during pregnancy.

Key words:

peripartum cardiomyopathy – heart failure – aetiology – diagnosis – treatment

Zdroje

1. Bauersachs J, Arrigo M, Hilfiker-Kleiner D et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association od the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016; 18(9): 1096– 1105. doi: 10.1002/ ejhf.586.

2. Biteker M, Kayatas K, Duman D et al. Peripartum cardiomyopathy: current state of knowledge, new developments and future directions. Current Cardiol Rev 2014; 10(4): 317– 326.

3. Ramaraj R, Sorrel VL. Peripartum cardiomyopathy: causes, diagnosis, and treatment. Cleve Clin J Med 2009; 76(5): 289– 296. doi: 10.3949/ ccjm.76a.08004.

4. Elliot P, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J 2008; 29(2): 270– 276. doi: 10.1093/ eurheartj/ ehm342.

5. Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on clinical cardiology, heart failure and transplantation comitee; Quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and Council on epidemiology and prevention. Circulation 2006; 113(14): 1807– 1816. doi: 10.1161/ CIRCULATIONAHA.106.174287.

6. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010; 121(20): 2169– 2175. doi: 10.1161/ CIRCULATIONAHA.109.929646.

7. Ware JS, Li J, Mazaika E et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016; 374(3): 233– 241. doi: 10.1056/ NEJMoa1505517.

8. Abboud J, Murad Y, Chen-Scarabelli C et al. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol 2007; 118(3): 295– 303. 10.1016/ j.ijcard.2006.08.005.

9. Ersbøll AS, Damm P, Gustafsson F et al. Peripartum cardiomyopathy: a systematic literature review. Acta Obstet Gynecol Scand 2016; 95(11): 1205– 1219. doi: 10.1111/ aogs.13005.

10. Koenig T, Bauersachs J, Hilfiker-Kleiner D. Bromocriptine for the treatment of peripartum cardiomyopathy. Card Fail Rev 2018; 4(1): 46– 49. doi: 10.15420/ CFR.2018:2:2.

11. Elkayam U, Goland S, Pieper PG et al. High-risk cardiac disease in pregnancy: part II. J Am Coll Cardiol 2016; 68(5): 502– 516. doi: 10.1016/ j.jacc.2016.05.050.

12. Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation 2016; 133(14): 1397– 1409. doi: 10.1161/ CIRCULATIONAHA.115.020491.

13. Midei MG, DeMent SH, Feldman AM, et al. Peripartum myocarditis and cardiomyopathy. Circulation 1990; 81(3): 922– 928.

14. Lim GB. Cardiomyopathies: Genetic overlap between peripartum and dilated cardiomyopathies. Nat Rev Cardiol 2016; 13(3): 121. doi: 10.1038/ nrcardio.2016.3.

15. Fett JD, Markham DW. Discoveries in peripartum cardiomyopathy. Trends Cardiovasc Med 2015; 25(5): 401– 406. doi: 10.1016/ j.tcm.2014.10.019.

16. Triebel J, Clapp C, Martínez de la Escalera G et al. Remarks on the prolactin hypothesis of peripartum cardiomyopathy. Front Endocrinol 2017; 8: 77. doi: 10.3389/ fendo.2017.00077.

17. Stapel B, Kohlhaas M, Ricke-Hoch M et al. Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J 2017; 38(5): 349– 361. doi: 10.1093/ eurheartj/ ehw086.

18. Bello NA, Arany Z. Molecular mechanisms of peripartum cardiomyopathy: a vascular/ hormonal hypothesis. Trends Cardiovasc Med 2015; 25(6): 499– 504. doi: 10.1016/ j.tcm.2015.01.004.

19. Liu S, Elkayam U, Naqvi TZ. Echocardiography in pregnancy. Curr Cardiol Rep 2016; 18(9): 92. doi: 10.1007/ s11886-016-0760-7.

20. Briasoulis A, Mocanu M, Marinescu K et al. Longitudinal systolic strain profiles and outcome in peripartum cardiomyopathy. Echocardiography 2016; 33(9): 1354– 1360. doi: 10.1111/ echo.13277.

21. Krejčí J, Poloczková H, Němec P. Current therapeutic concepts in peripartum cardiomyopathy. Curr Pharm Des 2015; 21(4): 507– 514.

22. Hilfiker-Kleiner D, Haghikia A, Nonhoff J et al. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J 2015; 36(18): 1090– 1097. doi: 10.1093/ eurheartj/ ehv009.

23. Gil KE, Pawlak A, Gil RJ et al. The role of invasive diagnostics and its impal on the treatment of dilated cardiomyopathy: A systematic review. Adv Med Sci 2016; 61(2): 331– 343. doi: 10.1016/ j.advms.2016.07.001.

24. Koenig T, Hilfiker-Kleiner D, Bauersachs J. Peripartum cardiomyopathy. Herz 2018; 43: 431– 437. doi: 10.1007/ s00059-018-4709-z.

25. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force fot he diagnosis and treatment of acute and chronic heasrt failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129– 2200. doi: 10.1093/ eurheartj/ ehw128.

26. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39(34): 3165– 3241. doi: 10.1093/ eurheartj/ ehy340.

27. Wojnicz R, Nowalany-Kozielska E, Wojciechowska Cet al. Randomized, placebo controled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Circulation 2001; 104(1): 39– 45.

28. Hilfiker-Kleiner D, Haghikia A, Berliner D et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomised study. Eur Heart J 2017; 38(35): 2671– 2679. doi: 10.1093/ eurheartj/ ehx355.

29. Duncker D, Westenfeld R, Konrad T et al. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fiction: a German multi-centre analysis. Clin Res Cardiol 2017; 106(8): 582– 589. doi: 10.1007/ s00392-017-1090-5.

30. Sliwa K, Petrie MC, Hilfiker-Kleiner D et al. Long-term prognosis, subsequent pregnancy, contraception and overal management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail 2018; 20(6): 951– 962. doi: 10.1002/ ejhf.1178.

31. Fett J, Mc Namara DM. Peripartum cardiomyopathy in 2015. Can J Cardiol 2016; 32(3): 286– 288. doi: 10.1016/ j.cjca.2015.08.015.

32. Blauwet LA, Delgado-Montero A, Ryo K et al. Right ventricular function in peripartum cardiomyopathy at present is associated withsubsequent left ventricular recovery and clinical outcomes. Circ Heart Fail 2016; 9(5): e002756. doi: 10.1161/ CIRCHEARTFAILURE.115.002756.

33. Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol 2014; 64(15): 1629– 1636. doi: 10.1016/ j.jacc.2014.07.961.

34. Basuray A, Fang JC. Management of patients with recovered systolic function. Prog Cardiovasc Dis 2016; 58(4): 434– 443. doi: 10.1016/ j.pcad.2016.01.003.